- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02199366
Study of Cardiac MRI in Patients With Left-Sided Breast Cancer Receiving Radiation Therapy
Prospective Pilot Study of Early Markers of Radiation-Induced Cardiac Injury in Patients With Left-Sided Breast Cancer Receiving Photon or Proton Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
As part of this study, participants will have a cardiac MRI at baseline and a follow-up cardiac MRI within 1 year after completion of standard radiation therapy for left-sided breast cancer. The cardiac MRI scans will be evaluated to determine if there are changes in cardiac function within 1 year after radiation treatment.
Patients will be asked to complete a questionnaire before and after treatment that asks about their health and any symptoms they may be having.
Physical exams and any other standard of care service or treatment will be at the discretion of the treating physician.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Florida
-
Jacksonville, Florida, United States, 32206
- University of Florida Proton Therapy Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Left-sided breast cancer stage I-III.
- Indications for adjuvant regional nodal and breast or chest wall radiation therapy (RT).
- Women and men are allowed.
- Must be at least 18 years old at time of consent.
Exclusion Criteria:
- Pregnant and/or breastfeeding women or patients of child-producing potential not willing to use contraception while on study.
- Prior history of cardiovascular disease per physician discretion.
- Stage 0 and IV breast cancer.
- Prior radiation therapy to chest.
- Concurrent trastuzumab per physician discretion.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Cardiac magnetic resonance (cardiac MRI)
Participants will have a cardiac MRI at baseline and within 1 year after completion of radiation therapy.
|
Participants will have a cardiac MRI at baseline and within 1 year after completion of radiation therapy.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of participants with changes in cardiac function.
Time Frame: 1 year after completion of radiation therapy
|
A change in cardiac function may include shifts from baseline measures of LV mass, strain, ejection fraction, and late gadolinium enhancement.
|
1 year after completion of radiation therapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with serious cardiac side effects.
Time Frame: 1 year after completion of radiation therapy
|
Includes myocardial infarction, valve disorder, congestive heart failure, and angina.
|
1 year after completion of radiation therapy
|
Mean quality of life score.
Time Frame: 1 year after radiation treatment
|
Comparison of baseline and post treatment quality of life questionnaires completed by participants.
|
1 year after radiation treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Julie A Bradley, MD, University of Florida Proton Therapy Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UFPTI 1419-BR02
- IRB201800163 (Other Identifier: UF IRB)
- UFJ 2014-116 (Other Identifier: UF IRB Old Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
Clinical Trials on Cardiac magnetic resonance (cardiac MRI)
-
RWTH Aachen UniversityHeidelberg UniversityCompletedAcute Myocardial InfarctionGermany
-
University Medical Center GroningenCompleted
-
Hospices Civils de LyonRecruiting
-
Centre Hospitalier Universitaire, AmiensCompletedHypertrophic Cardiomyopathy | Obstruction | EchocardiographyFrance
-
Alejandro Rodriguez Oviedo , MDTerminatedMyocardial Ischemia | Pneumonia, PneumococcalSpain
-
Cardiovascular Research Institute DublinActive, not recruitingCovid19 | Cardiomyopathies | SARS-CoV InfectionIreland
-
Mayo ClinicActive, not recruitingTricuspid RegurgitationUnited States
-
University of Maryland, BaltimoreTerminatedBreast Cancer | Mesothelioma | Thoracic Cancer | Thymic Cancer | Lung Cancer (Non-Small Cell)United States
-
Hari NarayanRecruitingHeart Failure | Cardiotoxicity | Pediatric CancerUnited States
-
Joshua KanterActive, not recruitingAortic Stenosis | Atrial Septal Defect | Aortic Coarctation | Patent Ductus Arteriosus | Cardiomyopathy | Post Heart Transplant Catheter ProcedureUnited States